Search Result

Results for "

lung+diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) Aldehyde Dehydrogenase (ALDH) (1) Aminoacyl-tRNA Synthetase (1) Aminopeptidase (1) Bacterial (4) CCR (1) CFTR (1) CXCR (1) Dipeptidyl Peptidase (1) Elastase (2) Endogenous Metabolite (1) Formyl Peptide Receptor (FPR) (2) Furin (1) HCV Protease (1) Interleukin Related (1) Leukotriene Receptor (1) Liposome (2) Mucin (1) NF-κB (1) Parasite (1) Phosphodiesterase (PDE) (3) PPAR (1) Prostaglandin Receptor (1) Reference Standards (2) ROCK (1) SARS-CoV (1) Sodium Channel (1) STAT (4) TGF-beta/Smad (1) TNF Receptor (1) Topoisomerase (1) TRP Channel (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (3) Endocrinology (1) Infection (9) Inflammation/Immunology (23) Metabolic Disease (3) Neurological Disease (3)
Oligonucleotides:	Cationic Lipids (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148096

STAT6-IN-1 1 Publications Verification	STAT	Inflammation/Immunology Cancer
STAT6-IN-1 (Compound 19a) is a STAT6 inhibitor with a high affinity for the SH2 domain of STAT6 (IC₅₀=0.028 µM). STAT6-IN-1 can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer .

HY-101283

HCH6-1 5 Publications Verification	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
HCH6-1 is a potent and competitive dipeptide antagonist of Formyl peptide receptor 1 (FPR1). HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist). HCH6-1 has protective effects against acute lung injury (ALI) in vivo and can be used for the research of FPR1-involved inflammatory lung diseases .

HY-147140

BOS-318 2 Publications Verification	Furin	Inflammation/Immunology
BOS-318 is a potent, slowly dissociating, highly selective, and cell-permeable furin inhibitor with IC₅₀ value of 1.9 nM. BOS-318 protects ENaC from subsequent activation by neutrophil elastase. BOS-318 can be used for the rsearch for CF lung disease .

HY-19929

Tanimilast CHF-6001	Phosphodiesterase (PDE) NF-κB Interleukin Related CXCR CCR TNF Receptor	Inflammation/Immunology
Tanimilast (CHF-6001) is an orally active and selective phosphodiesterase 4 inhibitor (IC₅₀=0.026 nM) with robust anti-inflammatory activity and suitable for topical pulmonary administration. Tanimilast increases cellular cAMP levels, and inhibits NF-κB signaling pathway. Tanimilast is used for the research of obstructive lung diseases .

HY-109163

Treprostinil palmitil INS-1009	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
Treprostinil palmitil is a long-acting inhaled pulmonary vasodilator prodrug of Treprostinil (HY-100441), formulated in a lipid nanoparticle (LNP). Treprostinil palmitil can inhibit pulmonary vascular remodeling induced by Su/Hx challenge in rats. Treprostinil palmitil can induce cough. Treprostinil palmitil demonstrates a sustained presence in the lungs with reduced systemic exposure and prolonged inhibition of hypoxia-induced pulmonary vasoconstriction in vivo. Treprostinil palmitil can be studied in research for pulmonary arterial hypertension and interstitial lung disease .

HY-113152

Hypogeic acid (50mg/ml in ethanol)	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Hypogeic acid is a fatty acid and endogenous metabolite, with a concentration of 50 mg/mL in ethanol. The plasma level of Hypogeic acid is negatively correlated with the prevalence of interstitial lung disease in idiopathic inflammatory myopathy. Hypogeic acid can be used in studies related to idiopathic inflammatory myopathy .

HY-150229

306-N16B	Liposome	Cancer
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .

HY-148092

PM-43I	STAT	Inflammation/Immunology Cancer
PM-43I is a potent STAT6 inhibitor and can reduce STAT6 phosphorylation level. PM-43I can be used in allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease and cancer research ^[1].

HY-108464A

Phenamil methanesulfonate	Sodium Channel TRP Channel	Metabolic Disease Inflammation/Immunology
Phenamil methanesulfonate, an analog of Amiloride (HY-B0285), is a more potent and less reversible epithelial sodium channel (ENaC) blocker with an IC₅₀ of 400 nM . Phenamil methanesulfonate is also a competive inhibitor of TRPP3 and inhibits TRPP3-mediated Ca ²⁺ transport with an IC₅₀ of 140 nM in a Ca ²⁺ uptake assay . Phenamil methanesulfonate is an intriguing small molecule to promote bone repair by strongly activating BMP signaling pathway . Phenamil methanesulfonate is used for the research of cystic fibrosis lung disease .

HY-168973

Fexlamose AER-01; MUC-031	Mucin	Inflammation/Immunology
Fexlamose (AER-01) is a thiol-modified carbohydrate agent with mucolytic property. Fexlamose cleaves disulfides to cause mucolysis. Fexlamose can be used for researchs of chronic obstructive pulmonary disease (COPD) and muco-obstructive lung diseases (MOLD) .

HY-148093

PM-81I	STAT	Inflammation/Immunology Cancer
PM-81I is a potent STAT6 inhibitor (targeting the SH2 structural domain) that effectively reduces STAT6 phosphorylation levels. PM-81I can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer ^[1].

HY-P990782

Efzofitimod	Aminoacyl-tRNA Synthetase	Inflammation/Immunology
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .

HY-12930

SPR719 4 Publications Verification VXc-486	Topoisomerase Bacterial	Infection
SPR719 (VXc-486) is an orally active gyrase B inhibitor, with bactericidal activity. SPR719 potently inhibits multiple agent-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis, with MICs of 0.03 to 0.30 μg/ml and 0.08 to 5.48 μg/ml, respectively. SPR719 is promising for research of lung disease caused by non-tuberculous mycobacteria (NTM) .

HY-103165

PSB-0788	Adenosine Receptor	Infection Cancer
PSB-0788 is a new selective high-affinity A_2B antagonist with IC₅₀ value of 3.64 nM and K_i value of 0.393 nM, respeactively. PSB-0788 can be used for the research for chronic inflammatory lung diseases .

HY-178821

ROCK2-IN-12	ROCK TGF-beta/Smad STAT	Inflammation/Immunology
ROCK2-IN-12 (Compound A25) is a selective ROCK2 inhibitor with an IC₅₀ of 7.0  nM for ROCK2 over ROCK1. ROCK2-IN-12 has potent antifibrotic effects via the TGF-β/Smad and ROCK2/STAT3 signaling pathways. ROCK2-IN-12 significantly reduces collagen deposition and reverses fibrotic progression in Bleomycin (HY-108345)-induced pulmonary fibrosis (PF) mouse models. ROCK2-IN-12 can be used for lung diseases like pulmonary fibrosis research .

HY-12733

AZD5248	Dipeptidyl Peptidase	Inflammation/Immunology
AZD5248 is a dipeptidyl peptidase 1 (DPP1) inhibitor that can be used for the research of chronic obstructive lung disease .

HY-W097753

4-MDM 4-Methoxydiphenylmethane	Aminopeptidase	Others
4-MDM (4-Methoxydiphenylmethane) is an orally active anti-inflammatory compound that selectively enhances the Leukotriene A₄ Hydrolase (LTA₄H) aminopeptidase enzyme activity. 4-MDM reduces the neutrophil recruitment in the lung by enhancing the degradation of proline-glycine-proline by LTA₄H, thereby reducing inflammation, and does not affect the epoxy-hydrolase activity of LTA₄H. 4-MDM can be used for research on lung diseases .

HY-106293

ICI-200880	Elastase	Inflammation/Immunology
ICI-200880 is a potent, selective and reversible human neutrophil elastase (HNE) inhibitor. ICI-200880 is promising for research of inflammatory lung diseases related to neutrophil elastase, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) .

HY-P4040

Ac-D-DGla-LI-Cha-C	HCV Protease	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Ac-D-DGla-LI-Cha-C is a potent HCV protease inhibitor peptide. Ac-D-DGla-LI-Cha-C can be used for the research of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases .

HY-168985

Mirivadelgat	Aldehyde Dehydrogenase (ALDH)	Cancer
Mirivadelgat is an activator of aldehyde dehydrogenase 2 activator. Mirivadelgat is promising for research of interstitial lung disease-pulmonary hypertension and cancers .

HY-120107

OAT-177	Parasite	Inflammation/Immunology
OAT-177 is a potent dual inhibitor targeting acidic mammalian chitinase (AMCase) and chitotriosidase (CHIT1) with an IC₅₀=14.2 nM for human AMCase and IC₅₀=232 nM for human CHIT1. OAT-177 is promising for research of chronic inflammatory and fibrotic-related lung diseases such as asthma and idiopathic pulmonary fibrosis .

HY-165407

Neltenexine	Elastase CFTR	Inflammation/Immunology
Neltenexine, a mucolytic agent, is an Elastase inhibitor. Neltenexine diminishes anion secretion in in bronchial epithelial cells by inhibiting the Cl− and HCO3- uptake via Na/K/2Cl++− and Na+/HCO3- cotransporter without blockade of the CFTR channel, and also diminishes anion secretion via stimulation of Cl−/HCO3- exchanger. Neltenexine significantly prevents pulmonary emphysema with a reduction of alveolar deformation in rat models induced by Elastase. Neltenexine can be used for lung diseases such as chronic obstructive pulmonary disease (COPD) research .

HY-131471

Zafirlukast metabolite M1	Leukotriene Receptor	Inflammation/Immunology
Zafirlukast metabolite M1 (compound 15) is an inhibitor of allergic lung diseases such as asthma and can antagonize the activity of leukotrienes .

HY-105647

Ambuphylline Bufylline	Phosphodiesterase (PDE)	Cardiovascular Disease
Ambuphylline (Bufylline) is a bronchodilator. Ambuphylline is a theophylline derivative possibly acting through phosphodiesterase inhibition. Ambuphylline can be used for the research of asthma and other lung diseases .

HY-N13380

6′‐O‐Galloylsalidroside	Others	Cardiovascular Disease Neurological Disease Metabolic Disease
6’-O-Galloylsalidroside is an active component of Rhodiola. 6’-O-Galloylsalidroside is promising for research of Alzheimer’s disease, lung diseases, cerebrovascular disease, diabetes, cardiovascular disease and aging-related diseases .

HY-151164

LasR-IN-2	Bacterial	Infection
LasR-IN-2 is a LasR inhibitor that forms H-bonding with TRY-56 residue. LasR-IN-2 can be used in the research of bacterial infection, neutropenia, severe burns and chronic lung disease in cystic fibrosis (CF) .

HY-162496

L-NBDNJ	Bacterial	Infection Inflammation/Immunology
L-NBDNJ, a glycomimetic, is an antivirulence agent. L-NBDNJ interferes with the expression of proteins regulating cytoskeleton assembly and organization of the host cell. L-NBDNJ has anti-inflammatory and anti-infective effects in models of cystic fibrosis (CF) lung disease infection .

HY-P991445

REGN3051	SARS-CoV	Infection
REGN3051 is a human IgG1 monoclonal antibody (mAb) targeting MERS CoV. REGN3051 reduces viral titers in the lungs of mice expressing human DPP4. REGN3051 decreases lung disease severity and viral replication in marmosets inoculated with MERS-CoV. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-171984

514O6,10	Liposome	Infection Inflammation/Immunology Cancer
514O6,10 is an ionizable lipidoid containing a branched-tail. 514O6,10 can be used to synthesize lipid nanoparticles (LNPs) for delivering mRNA to natural killer and dendritic cells within the lung. 514O6,10 can be used for the RNA therapies for lung diseases associated with immune cell dysregulation, including cancer, viral infections, and autoimmune disorders research .

HY-N18810

Mustard oil	Bacterial	Cardiovascular Disease Infection Inflammation/Immunology
Mustard oil has antibacterial and anti-inflammatory properties and can be used in research on skin diseases, lung diseases, arthritis, and cardiovascular complications.

HY-103165R

PSB-0788 (Standard)	Reference Standards Adenosine Receptor	Infection Cancer
PSB-0788 (Standard) is the analytical standard of PSB-0788 (HY-103165). This product is intended for research and analytical applications. PSB-0788 is a new selective high-affinity A2B antagonist with IC₅₀ value of 3.64 nM and K_i value of 0.393 nM, respeactively. PSB-0788 can be used for the research for chronic inflammatory lung diseases .

HY-179580

EL244	PPAR Phosphodiesterase (PDE)	Inflammation/Immunology
EL244 is a dua Autotaxin (ATX) (IC₅₀ = 50 nM) inhibitor and PPARγ (IC₅₀ = 1.3 μM; K_d = 1.3 μM) agonist. EL244 demonstrates low cytotoxicity in human HepG2 cells (EC₅₀ = 81.2 μM) with minimal inhibition of the cardiac hERG potassium channel (12% at 25 μM). EL244 significantly reduces pulmonary Lysophosphatidic Acid (LPA) levels, attenuates fibrosis, and restores respiratory function with limited systemic absorption in vivo. EL244 can be used for idiopathic pulmonary fibrosis and interstitial lung disease (ILD) research .

HY-101283R

HCH6-1 (Standard)	Formyl Peptide Receptor (FPR) Reference Standards	Inflammation/Immunology
HCH6-1 (Standard) is the analytical standard of HCH6-1 (HY-101283). This product is intended for research and analytical applications. HCH6-1 is a potent and competitive dipeptide antagonist of Formyl peptide receptor 1 (FPR1). HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist). HCH6-1 has protective effects against acute lung injury (ALI) in vivo and can be used for the research of FPR1-involved inflammatory lung diseases .

Cat. No.	Product Name

HY-L210

Anti-Rheumatic Arthritis Compound Library	1,883 compounds
Rheumatoid Arthritis (RA) is a autoimmune disease characterized by persistent joint inflammation. The pathology of RA includes immune cell infiltration, synovial lining proliferation, pannus formation, and the destruction of joint cartilage and bone, which is highly disabling. Due to long-term chronic inflammation, RA not only severely affects the quality of life of patients but can also damage multiple organs, leading to lung diseases, cardiovascular diseases, and malignant tumors. The pathogenesis of RA is complex, involving genetic, environmental, and immune factors. With the advancement of high-throughput screening technology, screening for compounds targeting JAK, CCR, MEK, MMP targets may contribute to the development of more effective drugs against Rheumatoid Arthritis (RA). MCE has collected 1,883 small molecule compounds with definite or potential anti-rheumatoid arthritis activity. This library is of significant value for researching the anti-RA drugs.

Anti-Rheumatic Arthritis Compound Library

1,883 compounds

Rheumatoid Arthritis (RA) is a autoimmune disease characterized by persistent joint inflammation. The pathology of RA includes immune cell infiltration, synovial lining proliferation, pannus formation, and the destruction of joint cartilage and bone, which is highly disabling. Due to long-term chronic inflammation, RA not only severely affects the quality of life of patients but can also damage multiple organs, leading to lung diseases, cardiovascular diseases, and malignant tumors. The pathogenesis of RA is complex, involving genetic, environmental, and immune factors. With the advancement of high-throughput screening technology, screening for compounds targeting JAK, CCR, MEK, MMP targets may contribute to the development of more effective drugs against Rheumatoid Arthritis (RA).

MCE has collected 1,883 small molecule compounds with definite or potential anti-rheumatoid arthritis activity. This library is of significant value for researching the anti-RA drugs.

Cat. No.	Product Name	Type

HY-150229

306-N16B	Biochemical Assay Reagents
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .

306-N16B

Biochemical Assay Reagents

306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .

Cat. No.	Product Name	Target	Research Area

HY-P4040

Ac-D-DGla-LI-Cha-C	HCV Protease	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Ac-D-DGla-LI-Cha-C is a potent HCV protease inhibitor peptide. Ac-D-DGla-LI-Cha-C can be used for the research of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990782

Efzofitimod	Aminoacyl-tRNA Synthetase	Inflammation/Immunology
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .

HY-P991445

REGN3051	SARS-CoV	Infection
REGN3051 is a human IgG1 monoclonal antibody (mAb) targeting MERS CoV. REGN3051 reduces viral titers in the lungs of mice expressing human DPP4. REGN3051 decreases lung disease severity and viral replication in marmosets inoculated with MERS-CoV. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

Hypogeic acid (50mg/ml in ethanol)	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Hypogeic acid is a fatty acid and endogenous metabolite, with a concentration of 50 mg/mL in ethanol. The plasma level of Hypogeic acid is negatively correlated with the prevalence of interstitial lung disease in idiopathic inflammatory myopathy. Hypogeic acid can be used in studies related to idiopathic inflammatory myopathy .

6′‐O‐Galloylsalidroside	Distylium racemosum Siebold & Zucc. Phenols Polyphenols Hamamelidaceae Plants Source Classification	Others
6’-O-Galloylsalidroside is an active component of Rhodiola. 6’-O-Galloylsalidroside is promising for research of Alzheimer’s disease, lung diseases, cerebrovascular disease, diabetes, cardiovascular disease and aging-related diseases .

Mustard oil	Structural Classification Extract	Bacterial
Mustard oil has antibacterial and anti-inflammatory properties and can be used in research on skin diseases, lung diseases, arthritis, and cardiovascular complications.

Cat. No.	Product Name		Classification

HY-150229

306-N16B		Cationic Lipids
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .

HY-171984

514O6,10		Cationic Lipids
514O6,10 is an ionizable lipidoid containing a branched-tail. 514O6,10 can be used to synthesize lipid nanoparticles (LNPs) for delivering mRNA to natural killer and dendritic cells within the lung. 514O6,10 can be used for the RNA therapies for lung diseases associated with immune cell dysregulation, including cancer, viral infections, and autoimmune disorders research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

lung+diseases

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products